Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Condition:   IDH1-mutant Cholangiocarcinoma Interventions:   Drug: Ivosidenib;   Drug: Recommended Combination Dose (RCD) of ivosidenib;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   Servier Bio-Innovation LLC;   Institut de Recherches Internationales Servier Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials